UCB stock: Oddo BHF cuts target from EUR 293.00 to EUR 260.00

Published on 10/21/2026 at 15:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA approved UCB's ZILBRYSQ autoinjector on October 20, 2026. UCB stock costs EUR 215.30 on October 21, 2026, down 1.69 percent versus Xetra close.

Analyst target and product update

Oddo BHF reduced its UCB target from EUR 293.00 to EUR 260.00 on October 20, 2026.
UCB received FDA approval for a ZILBRYSQ autoinjector on October 20, 2026.
UCB stock costs EUR 215.30 at Lang & Schwarz on October 21, 2026 at 3:36 p.m. CEST, down 1.69 percent versus the Xetra close of October 20, 2026.
UCB is scheduled to publish annual 2026 results on February 25, 2027.

Pop-Art-Comic eines Wissenschaftlers mit leuchtendem Reagenzglas im Labor, bunte Halbtonpunkte — UCB S.A., ISIN BE0003739530, präsentiert als farbenfrohe Pop-Art-Comic-Szene mit begeistertem Wissenschaftler im Labor, Illustration mit AI erstellt.

Oddo BHF reduced its UCB target from EUR 293.00 to EUR 260.00 on October 20, 2026, while retaining an outperform view, as Zonebourse reported. The EUR 260.00 target lies 20.76 percent above the EUR 215.30 Lang & Schwarz price. UCB stock was trading at EUR 215.30 at Lang & Schwarz on October 21, 2026 at 3:36 p.m. CEST, down 1.69 percent versus the Xetra close of October 20, 2026 at EUR 219.00.

ZILBRYSQ adds a new option

UCB announced on October 20, 2026 that the U.S. Food and Drug Administration had approved a once-daily autoinjector for ZILBRYSQ in adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive. The approval gives patients a second self-administration option alongside the prefilled syringe, according to Finanznachrichten. Complete dose delivery reached 99.80 percent across 449 autoinjector administrations in the supporting study.

Stock sits 25.63 percent below high

The current euro price is 9.04 percent above the 52-week low of EUR 197.45 and 25.63 percent below the 52-week high of EUR 289.50. UCB's year-to-date performance was minus 8.21 percent as of October 20, 2026, leaving the stock below its recent annual peak despite the longer-term target premium.

Valuation and next date

UCB had a market capitalization of EUR 41.1 billion and a price-to-earnings ratio of 18.64 on October 21, 2026. The company is scheduled to publish its annual 2026 results on February 25, 2027, according to the UCB calendar reported by Zonebourse.

Comparison with peers

UCB: down 1.69 percent, price-to-earnings ratio 18.64, market capitalization EUR 41.1 billion.

Sanofi (Euronext Paris, EUR): down 0.15 percent, price-to-earnings ratio 22.67, market capitalization EUR 88.0 billion.

AbbVie (NYSE, USD): down 0.74 percent, price-to-earnings ratio 80.86, market capitalization USD 507.1 billion.

What the target means for UCB

The revised EUR 260.00 target places the analyst view above the current euro price but below the 52-week high. For investors, the key tension is clear: the latest product approval adds another administration route, while the target reduction from EUR 293.00 signals a more cautious valuation stance.

Stock position after the target cut

UCB remains listed on Euronext Brussels under ticker UCB and operates as a biopharmaceutical company focused on immune-system and central-nervous-system diseases. At Lang & Schwarz, the stock stood at EUR 215.30 on October 21, 2026 at 3:36 p.m. CEST, down 1.69 percent versus the Xetra close of October 20, 2026 at EUR 219.00. The further course of trading is shown by the continuously updated real-time quote of UCB stock.